The median age was 53 (range: 35–71), and the majority of women had ER/PR positive/Her2-neu negative (n = 13, 54%), stage I (n = 13, 54%) or II (n = 7, 30%) breast cancer. This evidence concerns the gene ERBB2 and breast cancer.